4 recruiting, 1 active not recruiting, 1 terminated, 1 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
Follow Hormone Receptor Negative Breast Carcinoma: new trials by email Literature Review of Hormone Receptor Negative Breast Carcinoma trials Research Report on Hormone Receptor Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-16 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| ETHAN - ET for Male BC Tamoxifen, Anastrozole, Degarelix - Male Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 2 | Recruiting | Jose Pablo Leone | 60 | 2023-10-11 | 2026-08-24 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Onvansertib + Paclitaxel In TNBC Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Antonio Giordano, MD | 50 | 2022-09-30 | 2026-02-11 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 |
Triple Negative Breast Neoplasms (6) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Uterine Diseases (2) · Adenocarcinoma (1) · Breast Neoplasms, Male (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Inflammatory Breast Neoplasms (1) · Neoplasm, Residual (1) · Rectal Neoplasms (1)
Breast Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adnexal Diseases (3) · Breast Neoplasms (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3)
Paclitaxel (3) · abemaciclib (2) · ALX148 (1) · Anastrozole (1) · Androgen Antagonists (1) · Capecitabine (1) · Doxorubicin (1) · Everolimus (1) · Tamoxifen (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · onvansertib (1) · trastuzumab duocarmazine (1) · tucatinib (1) · zanidatamab (1)
NiKang Therapeutics, Inc. (2) · QuantumLeap Healthcare Collaborative (2) · Antonio Giordano, MD (1) · Jose Pablo Leone (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (7) · South Korea (1)
Paula R Pohlmann, MD, MSc, PhD (2) · Anthony Elias, MD (1) · Antonio C Giordano, MD, PhD (1) · Eric Winer, MD (1) · Jose Pablo Leone, MD (1) · Lisa A Carey, MD (1)